Science Explorer Back to mapMap
Discussion
Topic · Pulmonary and Respiratory Medicine

Cancer-related cognitive impairment studies

Cancer-related cognitive impairment studies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 12k research works in it since 1951. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the mechanisms and impact of chemotherapy-induced cognitive impairment in cancer patients, particularly focusing on breast cancer survivors. It covers topics such as the neurobiological basis of cognitive dysfunction, the role of inflammatory cytokines, longitudinal assessment of cognitive changes, and the effects of adjuvant treatments on cognition.

  • Chemotherapy
  • Cognitive Function
  • Breast Cancer
  • Neuropsychological Impact
  • Adjuvant Treatment
  • Cancer Survivors
  • Neurobiological Basis
  • Inflammatory Cytokines
  • Brain Structure
  • Longitudinal Study
Research works
12k
fractional, since 1951
In the world top 10%
1.2k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+43%
the tick is no change
Largest producer
United States
43% of the 10 largest, 2022-now
Cancer-related cognitive impairment studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Cancer-related cognitive impairment studies research?

By volume, the United States and China publish the most (1.3k and 635 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.3k works
  2. 2 China 635 works
  3. 3 India 157 works
  4. 4 United Kingdom 138 works
  5. 5 Germany 133 works
  6. 6 Australia 125 works
  7. 7 Canada 120 works
  8. 8 Italy 115 works
  9. 9 Netherlands 110 works
  10. 10 Spain 110 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 43.4%China: 21.9%India: 5.4%United Kingdom: 4.7%6 others listed: 24.6%43%largest
United States1,262 · 43.4%China635 · 21.9%India157 · 5.4%United Kingdom138 · 4.7%6 others listed713 · 24.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cancer-related cognitive impairment studies research?

By volume in 2022-now, Harvard University publishes the most Cancer-related cognitive impairment studies research, followed by University of North Carolina at Chapel Hill and The University of Texas MD Anderson Cancer Center.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 67 works
  2. 2 University of North Carolina at Chapel HillUnited States 32 works
  3. 3 The University of Texas MD Anderson Cancer CenterUnited States 27 works
  4. 4 National Institutes of HealthUnited States 27 works
  5. 5 Mayo ClinicUnited States 26 works
  6. 6 University of TorontoCanada 25 works
  7. 7 The Ohio State UniversityUnited States 23 works
  8. 8 University of PittsburghUnited States 21 works
  9. 9 University of California, San FranciscoUnited States 21 works
  10. 10 Nanjing Medical UniversityChina 19 works

Who are the leading researchers in Cancer-related cognitive impairment studies?

The most-cited researchers publishing on Cancer-related cognitive impairment studies include Hermann Brenner, John Q. Trojanowski and Luigi Ferrucci.

  1. 1 Hermann Brenner Germany 343k citations
  2. 2 John Q. Trojanowski United States 286k citations
  3. 3 Luigi Ferrucci United States 281k citations
  4. 4 Hagop M. Kantarjian United States 273k citations
  5. 5 JoAnn E. Manson United States 263k citations
  6. 6 Amirhossein Sahebkar Iran 258k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Cancer-related cognitive impairment studies?

The most cited paper in Cancer-related cognitive impairment studies is "Mild Cognitive Impairment" (Ronald C. Petersen, Glenn E. Smith, Stephen C. Waring et al., 1999), with 9,076 citations. Next come "The Functional Assessment of Cancer Therapy scale: development and validation of the general measure." (6,104) and "Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable" (3,064).

Most cited papers
#PaperReleasedCitations
1 Mild Cognitive Impairment Ronald C. Petersen, Glenn E. Smith, Stephen C. Waring et al. · Archives of Neurology Mar 1999 9,076
2 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. David F Cella, David S. Tulsky, Geoffrey V. Gray et al. · Journal of Clinical Oncology Mar 1993 6,104
3 Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable Kristin L. Campbell, Kerri M. Winters‐Stone, Joachim Wiskemann et al. · Medicine & Science in Sports & Exercise Open access 17 Oct 2019 3,064
4 Interpreting the significance of changes in health-related quality-of-life scores. David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology 1998 2,991
5 Cancer treatment and survivorship statistics, 2012 Rebecca L. Siegel, Carol E. Desantis, Katherine S. Virgo et al. · CA A Cancer Journal for Clinicians Open access 14 Jun 2012 2,959
All 100 most cited papers, with filters and sorting

Where is Cancer-related cognitive impairment studies research done?

The largest centres of Cancer-related cognitive impairment studies research in 2022-now are Beijing (China), Boston (United States), Seoul (South Korea) and New York (United States).

Largest cities, 2022-now

  1. 1 BeijingChina 69 works
  2. 2 BostonUnited States 63 works
  3. 3 SeoulSouth Korea 54 works
  4. 4 New YorkUnited States 52 works
  5. 5 ShanghaiChina 49 works
  6. 6 LondonUnited Kingdom 47 works
  7. 7 HoustonUnited States 45 works
  8. 8 GuangzhouChina 43 works
  9. 9 TorontoCanada 35 works
  10. 10 MelbourneAustralia 34 works
See Cancer-related cognitive impairment studies on the map

Where is the best place to study Cancer-related cognitive impairment studies?

Among universities, judged by research, Harvard University, University College London and Ain Shams University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 15.61%fractional works in this field (log) →share of work in the world top 10% →University College L…University of Gothen…Ain Shams UniversityHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 71.810.8%5.7×67 +44.0%
2University College LondonUnited Kingdom 63.024.8%1.8×10 +27.7%
3Ain Shams UniversityEgypt 59.317.6%4.7×12 +69.7%
4University of GothenburgSweden 55.118.9%5.4×10 +146.4%
5University of RochesterUnited States 54.48.5%9.5×16 +34.7%
6Chinese University of Hong KongChina 53.617.8%3.8×10 +34.2%
7University of AmsterdamNetherlands 53.214.9%3.8×8 +21.0%
8University of MiamiUnited States 51.712.4%6.6×15 +69.8%
9University of PittsburghUnited States 50.610.4%7.2×21 +93.2%
10Fudan UniversityChina 50.620.0%2.0×12 +83.7%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Cancer-related cognitive impairment studies, country by country

Is Cancer-related cognitive impairment studies research growing?

Output in 2022-2025 was 43% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Cancer-related cognitive impairment studies.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cancer-related cognitive impairment studies as a percentage of every work published that year, 0.016% in 2024.

still counting0.010%0.020%Cancer-related cognitive impairment studies0.019% in 202519801990200020102020

Fractional works of Cancer-related cognitive impairment studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Cancer-related cognitive impairment studies10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Cancer-related cognitive impairment studies. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.